

Government of the District of Columbia
Office of the Chief Financial Officer



Glen Lee
Chief Financial Officer

MEMORANDUM


TO: The Honorable Phil Mendelson
Chairman, Council of the District of Columbia

FROM: Glen Lee
Chief Financial Officer

DATE: July 1, 2024

SUBJECT: Fiscal Impact Statement – Cost-Free Coverage for Prostate Cancer Screening Amendment Act of 2024

REFERENCE: Bill 25-229 - Draft Committee Print as provided to the Office of Revenue Analysis on June 25, 2024



Conclusion

Funds are sufficient in the fiscal year 2024 budget and fiscal year 2025 through fiscal year 2028 budget and financial plan to implement the bill.

Background

Currently, each individual and group health insurance plan issued or renewed in the District of Columbia must provide coverage for prostate cancer screening. The bill requires¹ health insurers to provide this coverage at no cost to plan members. Health insurers are prohibited from imposing deductibles, coinsurance, copayments, or other cost-sharing requirements, except to the extent that coverage without cost-sharing would disqualify the individual from a high deductible health benefit plan. Insurers must cover no less than one prostate-specific antigen test and one digital rectal exam per year.

Financial Plan Impact

Funds are sufficient in the fiscal year 2024 budget and fiscal year 2025 through fiscal year 2028 budget and financial plan to implement the bill. All health insurers operating in the District, including Medicaid and the D.C. Health Care Alliance, already cover prostate cancer screenings. The bill would

¹ By amending Section 3 of the Prostate Cancer Screening Insurance Coverage Requirement Act of 2002, effective March 25, 2003 (D.C. Law 14-233; D.C. Official Code § 31-2952).

The Honorable Phil Mendelson

FIS: Bill 25-229, "Cost-Free Coverage for Prostate Cancer Screening Amendment Act of 2024," Draft
Committee Print as provided to the Office of Revenue Analysis on June 25, 2024

reduce out-of-pocket costs for District residents with private health insurance coverage that currently requires deductibles, coinsurance, copayments, or other cost-sharing requirements for prostate cancer screenings.